Released Nov 4, 2026, after the close
10-Q filed Nov 4, 2026, 33 days after period end · 0000718937-26-000041
STAAR delivered third-quarter net sales of $83.4 million, a 12% decrease from $94.7 million in the same period last year.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $83.41M | $94.73M | $88.59M | $80.31M |
| Net Income | $5.58M | $8.88M | $9.98M | $4.82M |
Staar Surgical Co · CIK 718937 · Engraved from SEC EDGAR
| EPS Diluted | $0.11 | $0.18 | $0.20 | $0.10 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
STAAR reported third-quarter 2026 net sales of $83.4 million, a 12% decrease from $94.7 million in the same period last year.¶1
Third-quarter net income was $5.6 million, or $0.11 per diluted share, down from $8.9 million, or $0.18 per diluted share, in the prior-year quarter.¶2
Adjusted EBITDA was $14.4 million, or $0.28 per diluted share, down from $34.7 million, or $0.69 per diluted share, in the prior-year quarter.¶3
The Board authorized a share repurchase program allowing the Company to repurchase up to $50 million of its outstanding common stock, and the Company has no outstanding debt.¶4
Cash, cash equivalents, and investments available for sale totaled $206.4 million as of October 2, 2026, compared to $181.5 million at the end of the second quarter 2026.¶4